Associations Between Lifetime Classic Psychedelic Use and Markers of Physical Health

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2021 Mar 15

PMID 33719688

Citations 22

Authors

Otto Simonsson

James D Sexton

Peter S Hendricks

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, there has been significant research on the mental health effects of classic psychedelic use, but there is very little evidence on how classic psychedelics might influence physical health.

Aims: The purpose of the present study was to investigate the associations between lifetime classic psychedelic use and markers of physical health.

Methods: Using data from the National Survey on Drug Use and Health (2015-2018) with 171,766 (unweighted) adults aged 18 or above in the United States, the current study examined the associations between lifetime classic psychedelic use and three markers of physical health (self-reported overall health, body mass index, and heart condition and/or cancer in the past 12 months) while controlling for a range of covariates.

Results: Respondents who reported having tried a classic psychedelic at least once in their lifetime had significantly higher odds of greater self-reported overall health and significantly lower odds of being overweight or obese versus having a normal weight. The association between lifetime classic psychedelic use and having a heart condition and/or cancer in the past 12 months approached conventional levels of significance, with lower odds of having a heart condition and/or cancer in the past 12 months for respondents who had tried a classic psychedelic at least once.

Conclusion: The results of the present study suggest that classic psychedelics may be beneficial to physical health. Future research should investigate the causal effects of classic psychedelics on physical health and evaluate possible mechanisms.

Citing Articles

Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?.

Barnett B, Anand A, Dewey E, Smith D, Nayak S, Bruckman D Psychedelic Med (New Rochelle). 2025; 2(2):74-86.

PMID: 40051580 PMC: 11613523. DOI: 10.1089/psymed.2023.0027.

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice.

Aday J, Skiles Z, Eaton N, Fredenburg L, Pleet M, Mantia J Psychedelic Med (New Rochelle). 2025; 1(1):27-37.

PMID: 40047007 PMC: 11658662. DOI: 10.1089/psymed.2022.0004.

Effects of psilocybin on body weight, body composition, and metabolites in male and female mice.

Shakir J, Pedicini M, Bullock B, Hoen P, Macias L, Freiman J Physiol Behav. 2024; 284:114627.

PMID: 38964565 PMC: 11323168. DOI: 10.1016/j.physbeh.2024.114627.

Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.

Kolasa M, Nikiforuk A, Korlatowicz A, Solich J, Potasiewicz A, Dziedzicka-Wasylewska M Psychopharmacology (Berl). 2024; .

PMID: 38963553 DOI: 10.1007/s00213-024-06644-3.

Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.

Vina S J Racial Ethn Health Disparities. 2024; .

PMID: 38753105 DOI: 10.1007/s40615-024-02023-y.

References

Davis A, Barrett F, May D, Cosimano M, Sepeda N, Johnson M . Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2020; 78(5):481-489. PMC: 7643046. DOI: 10.1001/jamapsychiatry.2020.3285. View

Luoma J, Chwyl C, Bathje G, Davis A, Lancelotta R . A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. J Psychoactive Drugs. 2020; 52(4):289-299. PMC: 7736164. DOI: 10.1080/02791072.2020.1769878. View

van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W . Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res. 2010; 16(4):202-7. DOI: 10.1159/000317249. View

Winkelman M . Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Curr Drug Abuse Rev. 2015; 7(2):101-16. DOI: 10.2174/1874473708666150107120011. View

Johnson M, Garcia-Romeu A, Cosimano M, Griffiths R . Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014; 28(11):983-92. PMC: 4286320. DOI: 10.1177/0269881114548296. View

Krebs T, Johansen P . Over 30 million psychedelic users in the United States. F1000Res. 2014; 2:98. PMC: 3917651. DOI: 10.12688/f1000research.2-98.v1. View

Levola J, Rose R, Mustonen A, Sarala M, Miettunen J, Koskela J . Association of age at first drink and first alcohol intoxication as predictors of mortality: a birth cohort study. Eur J Public Health. 2020; 30(6):1189-1193. DOI: 10.1093/eurpub/ckaa134. View

Sexton J, Nichols C, Hendricks P . Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. Front Psychiatry. 2020; 10:896. PMC: 7026018. DOI: 10.3389/fpsyt.2019.00896. View

Flanagan T, Nichols C . Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018; 30(4):363-375. DOI: 10.1080/09540261.2018.1481827. View

10.

Nichols C . Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases. Cardiovasc Psychiatry Neurol. 2009; 2009:475108. PMC: 2790184. DOI: 10.1155/2009/475108. View

11.

Pisano V, Putnam N, Kramer H, Franciotti K, Halpern J, Holden S . The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol. 2017; 31(5):606-613. DOI: 10.1177/0269881117691453. View

12.

Rucker J, Iliff J, Nutt D . Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2017; 142:200-218. DOI: 10.1016/j.neuropharm.2017.12.040. View

13.

Heron M . Deaths: Leading Causes for 2017. Natl Vital Stat Rep. 2020; 68(6):1-77. View

14.

Kessler R, Andrews G, Colpe L, Hiripi E, Mroczek D, Normand S . Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002; 32(6):959-76. DOI: 10.1017/s0033291702006074. View

15.

Murphy-Beiner A, Soar K . Ayahuasca's 'afterglow': improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology (Berl). 2020; 237(4):1161-1169. DOI: 10.1007/s00213-019-05445-3. View

16.

Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S . The Australian drug harms ranking study. J Psychopharmacol. 2019; 33(7):759-768. DOI: 10.1177/0269881119841569. View

17.

Sexton J, Crawford M, Sweat N, Varley A, Green E, Hendricks P . Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. J Psychopharmacol. 2019; 33(9):1058-1067. DOI: 10.1177/0269881119827796. View

18.

Goldberg S, Pace B, Nicholas C, Raison C, Hutson P . The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res. 2020; 284:112749. DOI: 10.1016/j.psychres.2020.112749. View

19.

Johansen P, Krebs T . Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015; 29(3):270-9. DOI: 10.1177/0269881114568039. View

20.

Johnson M, Griffiths R, Hendricks P, Henningfield J . The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018; 142:143-166. PMC: 6791528. DOI: 10.1016/j.neuropharm.2018.05.012. View